In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: Comparison with rapamycin

Pharmaceutical Research

Volumn 15, Issue 11, 1998, Pages 1666-1672

  Crowe, Andrew ^a   Lemaire, Michel ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Caco 2; P glycoprotein; Probenecid; Rapamycin; SDZ RAD; Verapamil

Indexed keywords

EVEROLIMUS; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; CELL STRAIN CACO 2; DRUG ABSORPTION; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; PRIORITY JOURNAL;

ANIMALS; CACO-2 CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL ABSORPTION; MANNITOL; PROPRANOLOL; RATS; RATS, WISTAR; SIROLIMUS; VERAPAMIL;

EID: 0031786057     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011940108365     Document Type: Article

References (28)

1. V. P. Shah, A. Yacobi, W. H. Barr, L. Z. Benet, D. Breimer, M. R. Dobrinska, L. Endrenyi, W. Fairweater, W. Gillespie, M. A. Gonzalez, J. Hooper, A. Jackson, L. J. Lesko, K. K. Midha, P. K. Noonan, R. Patnaik, and R. L. Williams. Evaluation of orally administered highly variable drugs and drug formulations. Pharm. Res. 13:1590-1594 (1996).
2. R. Morris. Modes of action of FK506, cyclosporin A, and rapamycin. Transplant. Proc. 26:3272-3275 (1994).
3. G. M. Ferron, E. V. Mishina, J. J. Zimmerman, and W. J. Jusko. Population pharmacokinetics of sirolimus in kidney transplant patients. Clin. Pharmacol. Ther. 61:416-428 (1997).
4. C. Cordon-Cardo, J. P. O'Brien, D. Casals, L. Rittman-Grauer, J. L. Biedler, M. R. Melamed, and J. R. Bertino. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA 86:695-698 (1989).
5. F. Thiebaut, T. Tsuruo, H. Hamada, M. M. Gottesman, I. Pastan, and M. C. Willingham. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84:7735-7738 (1987).
6. P. F. Augustijns, T. P. Bradshaw, L. L. Gan, R. W. Hendren, and D. R. Thakker. Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporin A transport. Biochem. Biophys. Res. Com. 197:360-365 (1993).
7. T. Hoof, A. Demmer, U. Christians, and B. Tümmler. Reversal of multidrug resistance in Chinese hamster ovary cells by the immunosuppressive agent rapamycin. Eur. J. Pharm. Mol. Biol. 246:53-58 (1993).
8. S. P. Cole, G. Bhardwaj, J. H. Gerlach, J. E. MacKie, C. E. Gram, K. C. Almquist, A. J. Stewart, E. U. Kurz, A. M. Duncan, and R. G. Deeley. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654 (1992).
9. T. Nguyen and S. Gupta. Leukotriene C4 secretion from normal murine mast cells by a probenecid-Sensitive and multidrug resistance-associated protein-independent mechanism. J. Immunol. 158:4916-4920 (1997).
10. P. Artursson, K. Palm, and K. Luthman. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug. Del. Rev. 22:67-84 (1996).
11. E. Hofsli, and J. Nissen-Myer. Reversal of multidrug resistance by lipophilic drugs. Cancer Res. 50:3997-4002 (1990).
12. S. Gollapudi, C. H. Kim, B. Tram, S. Sangha, and S. Gupta. Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ARD cells. Cancer Chemother. Pharmacol. 40:150-158 (1997).
13. P. Artursson. Epithelial Transport of Drugs in Cell Culture. I: A model for studying the passive diffusion of drugs over intestinal absorbtive (Caco-2) cells. J. Pharm. Sci. 79:476-482 (1990).
14. P. Artursson and J. Karlsson. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Comm. 175:880-885 (1991).
15. B. H. Stewart, O. H. Chan, R. H. Lu, E. L. Reyner, H. L. Schmid, H. W. Hamilton, B. A. Steinbaugh, and M. D. Taylor. Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: Relationship to absorption in humans. Pharm. Res. 12:693-699 (1995)
16. V. C. Dias, and R. W. Yatscoff. Investigation of rapamycin transport and uptake across absorptive human intestinal cell monolayers. Clin. Biochem. 27:31-36 (1994).
17. F. Delie and W. Rubas. A Human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: Advantages and limitations of the Caco-2 model. Crit. Rev. Ther. Drug Carr. Sys. 14:221-286 (1997).
18. M. M. Nerurkar, N. F. H. Ho, P. S. Burton, T. J. Vidmar, and R. T. Borchardt. Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. J. Pharm. Sci. 86:813-821 (1997).
19. P. Wils, V. Phung-Ba, A. Warnery, D. Lechardeur, S. Raeissi, I. Hidalgo, and D. Scherman. Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem. Pharm. 48:1528-1530 (1994).
20. I. Brock, D. R. Hipfner, B. S. Nielsen, P. B. Jensen, R. G. Deeley, S. P. Cole, and M. Sehested. Sequential coexpression of the multidrug resistance genes MRP and mdrl and their products in VP-16 etoposide)-selected H60 small cell lung cancer cells. Cancer Res. 55:459-462 (1995).
21. E. Dolfini, T. Dasdia, G. Arancia, A. Molinari, A. Calcabrini, R. J. Scheper, M. J. Flens, M. B. Gariboldi, and E. Monti. Characterization of a clonal human colon adenocarcinoma line intrinsically resistant to doxorubicin. Br. J. Cancer 76:67-76 (1997).
22. R. Evers, G. J. Zaman, L. van Deemter, H. Jansen, J. Calafat, L. C. Oomen, R. P. Elferink, P. Borst, and A. H. Schinkel. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J. Clin. Invest. 97:1211-1218 (1996).
23. M. Kavallaris. The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance. Anti-Cancer Drugs 8:17-25 (1997).
24. L. L. Gan, M. A. Moseley, B. Khosla, P. F. Augustijns, T. P. Bradshaw, R. W. Hendren, and D. R. Thakker. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: Interaction between the two biochemical barriers to intestinal transport. Drug Met. Dis. 24:344-349 (1996).
25. L. L. Gan and D. R. Thakker. Application of the Caco-2 model in the design and development of orally active drugs: Elucidation of biochemical and physical barriers posed by the intestinal epithelium. Adv. Drug. Del. Rev. 23:77-98 (1997).
26. V. J. Wacher, L. Salphati, and L. Z. Benet. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Del. Rev. 20:99-112 (1996).
27. C. L. Crespi, B. W. Penman, and M. Hu. Development of Caco-2 cells expressing high levels of cDNA-derived cytochrome P4503A4. Pharm. Res. 13:1635-1641 (1996).
28. U. Fagerholm, M. Johansson, and H. Lennernäs. Comparison between permeability coefficients in rat and human jejunum. Pharm. Res. 13:1336-1342 (1996).